117 related articles for article (PubMed ID: 36602021)
1. A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan.
Liu Y; Goh CH; Qiu H; Huang KC; Chung H; Saadoun C
Ann Pharmacother; 2023 Sep; 57(9):1053-1061. PubMed ID: 36602021
[TBL] [Abstract][Full Text] [Related]
2. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
4. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.
Zhdanava M; Ding Z; Manceur AM; Zhao R; Holiday C; Kachroo S; Izanec J; Pilon D
Curr Med Res Opin; 2023 Sep; 39(9):1215-1225. PubMed ID: 37563994
[TBL] [Abstract][Full Text] [Related]
6. Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab.
Zhdanava M; Ding Z; Manceur AM; Muser E; Lefebvre P; Holiday C; Lafeuille MH; Pilon D
Curr Med Res Opin; 2023 Apr; 39(4):533-543. PubMed ID: 36752586
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns in Newly Diagnosed Patients with Crohn's Disease Who Received Biologics Following Diagnosis: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Medical Claims Database in Japan.
Hirai F; Uda A; Ota M; Takemura Y; Tanaka K; Iwakiri R
Digestion; 2023; 104(2):109-120. PubMed ID: 36450239
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
[TBL] [Abstract][Full Text] [Related]
9. Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumab.
Zhdanava M; Zhao R; Manceur AM; Ding Z; Kachroo S; Holiday C; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Aug; 29(8):907-916. PubMed ID: 37523319
[No Abstract] [Full Text] [Related]
10. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.
Yokoyama S; Asano T; Nagano K; Tsuchiya H; Takagishi M; Tsujioka S; Miura N; Matsumoto T
J Gastroenterol Hepatol; 2021 Nov; 36(11):3069-3076. PubMed ID: 34180096
[TBL] [Abstract][Full Text] [Related]
12. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
13. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.
Kim FS; Patel PV; Stekol E; Ali S; Hamandi H; Heyman MB; Verstraete SG
J Pediatr Gastroenterol Nutr; 2021 Nov; 73(5):610-614. PubMed ID: 34415711
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
16. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
Kappelman MD; Adimadhyam S; Hou L; Wolfe AE; Smith S; Simon AL; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett LE; Haynes K; Selvan M; Ma Q; Nair V; Burris J; Dorand JE; Dawwas GK; Lewis JD; Long MD
Am J Gastroenterol; 2023 Apr; 118(4):674-684. PubMed ID: 36508681
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
[TBL] [Abstract][Full Text] [Related]
18. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Ustekinumab in Crohn's Disease With and Without Concurrent Autoimmune Skin Disease.
Fradkov E; Sheehan J; Cushing K; Higgins PDR
Inflamm Bowel Dis; 2022 Jun; 28(6):895-904. PubMed ID: 34591972
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
